Successor drug to Vioxx faces uphill battle in FDA approval

Vioxx’s maker, Merck & Co., is asking the Food and Drug Administration to approve a successor to the pulled drug Vioxx that was found to increase the risk of heart attack and stroke. This week, an FDA advisory committee will hold a public meeting on the new drug Arcoxia, a Cox-2 inhibitor. The FDA is expected to rule before May on whether to the Vioxx successor.

Search

Disclaimer

The purpose of this blog is to deliver news and information that is relevant to our areas of practice. The news and information reported on this blog represent the legal actions of attorneys throughout the United States. Our firm does not claim to represent plaintiffs in all of the lawsuits, settlements, and jury verdicts reported, only those noted as Levin & Perconti cases.